Glaukos price target raised to $145 from $130 at Stifel

Stifel raised the firm’s price target on Glaukos to $145 from $130 and keeps a Buy rating on the shares. The firm’s survey of 26 iDose-trained surgeons that it estimates represent about 20% of the installed base finds reimbursement on iDose’s new, unique J-code is beginning to come through for doctors and “importantly” its checks show how consistent and predictable J-code reimbursement “will be crucial toward driving increased utilization,” the analyst tells investors.